Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Nov 2026

Harnessing the Immune System in Hepatocellular Carcinoma Targeting: Mechanistic Insights and Therapeutic Potential of Natural Products and Traditional Chinese Medicine

Abstract Hepatocellular carcinoma (HCC) is highly malignant, and most patients are diagnosed at intermediate or advanced stages. Current regimens, including surgery, targeted therapy and immune checkpoint inhibitors (ICIs), are limited by low response rates, drug resistance, prominent toxicities and high costs, so safe...

Li-Yuan Hao, Li-Wei Li, Yi-Cheng Chen et al. · 0 citations
Review Open access Sep 2026

Nanotherapeutic Strategies for MASLD: From Pathological Mechanisms to Targeted Delivery Systems

Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive metabolic liver disorder driven by hepatic lipid overload, oxidative stress, mitochondrial dysfunction, innate immune activation, insulin resistance, gut–liver axis dysregulation, and liver fibrosis. These interconnected patholog...

Na Li, Dong-Qi Zhou, Fang-Hang Ye et al. · 0 citations
#gene editing Review Open access Oct 2026

Metabolic-epigenetic regulation of the HBV cccDNA reservoir: pathways underpinning viral persistence

Preclinical and clinical therapeutic strategies targeting the metabolic-epigenetic microenvironment, viral assembly, antigen secretion, and cccDNA modulation to achieve a functional cure for HBV infection are summarized.

Qing Peng, Li-Yuan Hao, Sheng-Hao Li et al. · 0 citations
Open access Sep 2026

Deciphering early molecular responses to aristolactam I associated with hepatocellular carcinoma: Computational prediction of a core gene signature and identification of transcription-translation uncoupling under acute aristolactam I exposure.

Aristolochic acid I (AAI) is a potent hepatocarcinogen mainly activated to aristolactam I (ALI). The molecular mechanisms driving ALI‑associated hepatocellular carcinoma (HCC), particularly post‑transcriptional events linking acute liver injury to malignant transformation, remain poorly defined. Here, we integrated pha...

Qing Peng, L. Hao, Sheng-Hao Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.